Intravenous immunoglobulin for rheumatic diseases

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors’ objectives
<p>Intravenous immunoglobulin (IVIG) therapy is used to provide passive immunity or to alter the immune response by increasing an individual’s antibody titer and antigen-antibody reaction potential. IVIG has been investigated as a treatment for patients with rheumatic diseases, with the goals of alleviating symptoms and inducing sustained remissions from disease activity through anti-inflammatory and immunomodulatory effects.</p>

Timeliness warning
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Immunoglobulins, Intravenous /therapeutic use; Rheumatic Diseases /drug therapy

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

AccessionNumber
32006000994

Date bibliographic record published
11/10/2006

Date abstract record published
12/05/2010